Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover dose-ranging study of subcutaneous Cinryze with rHuPH20 for hereditary angioedema prophylaxis
2012-000083-24Phase 2Terminated
- Sponsor
- ViroPharma Incorporated
- Start
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of c1-esterase inhibitor and hyaluronidase in hereditary angioedema (HAE) (2 arms), sponsored by ViroPharma Incorporated. Primary endpoint: Normalized number of angioedema attacks. Started Mar 2012; status: terminated.
02
Drugs
c1-esterase inhibitorhyaluronidase
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2012-000083-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000083-24.